Ocular Therapeutix™ Announces Completion of Debt Refinancing
$25.0 Million Term Loan with MidCap Financial and Silicon Valley Bank
Cash Runway Extended into Third Quarter of 2019
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and
commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has closed a refinancing
of its existing debt by entering into a new $25.0 million term loan with MidCap Financial and Silicon Valley Bank.
The 5-year term loan facility allows for an expansion of the Company’s prior $18 million credit facility to $25.0 million, all
of which was drawn at closing. The proceeds from the loan were used to repay the approximately $12.3 million remaining balance
under the prior facility and provide an additional $12.0 million of new funds, net of expenses and fees. The restated and amended
agreement extends the term of the credit facility until December 21, 2023 and permits the Company to make interest-only payments
until January 1, 2021.
“We are pleased with the expansion and extension of our credit facility which not only strengthens our balance sheet with net
new funds of $12.0 million but also improves near term cash flow through interest-only payments for the next 24 months,
collectively extending the Company’s cash runway, based on current plans and forecasted expenses, into the third quarter of 2019,”
said Donald Notman, Chief Financial Officer.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular pain
following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical
development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. The
Company’s earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of
intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the
treatment of retinal diseases. These intravitreal implants include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap.
Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract
surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans, and prospects for the Company, including the
commercialization of ReSure Sealant, DEXTENZA® or any of the Company’s product candidates; the development and
regulatory status of the Company’s product candidates, such as the Company’s regulatory submissions for and the timing and conduct
of, or implications of results from, clinical trials of DEXTENZA for the treatment of post-surgical ocular inflammation and the
prospects for approvability of DEXTENZA for post-surgical ocular inflammation or any other indications, OTX-TP for the treatment of
primary open-angle glaucoma and ocular hypertension, OTX-TIC for the treatment of primary open-angle glaucoma and ocular
hypertension, OTX-TKI for the treatment of retinal diseases including wet AMD, and OTX-IVT as an extended-delivery formulation of
the VEGF trap aflibercept for the treatment of retinal diseases including wet AMD; the Company’s post-approval studies of
ReSure® Sealant and the Company’s ongoing communications with the U.S. Food and Drug Administration regarding the
Company’s appeal of the warning letter it received regarding ReSure Sealant; the ongoing development of the Company’s
extended-delivery hydrogel depot technology; the potential utility of any of the Company’s product candidates; the potential
benefits and future operation of the collaboration with Regeneron Pharmaceuticals, including any potential future payments
thereunder; the sufficiency of the Company’s cash resources and other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend", "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties
that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those
related to the timing and costs involved in commercializing ReSure Sealant, DEXTENZA or any product candidate that receives
regulatory approval, including the conduct of post-approval studies, the ability to retain regulatory approval of ReSure Sealant,
DEXTENZA or any product candidate that receives regulatory approval, the initiation, timing and conduct of clinical trials,
availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific
approach and general development progress, the availability or commercial potential of the Company’s product candidates, the
sufficiency of cash resources, the Company’s existing indebtedness, the ability of the Company’s creditors to accelerate the
maturity of such indebtedness upon the occurrence of certain events of default, the outcome of the Company’s ongoing legal
proceedings and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained
in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of
this release.
Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com
or
Westwicke Partners
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181228005033/en/